Neurokine Pharmaceuticals Inc.
OTC Bulletin Board : NEUKF

Neurokine Pharmaceuticals Inc.

February 03, 2011 09:03 ET

Neurokine Signs Contract with Clinical Investigation Group to Initiate Phase II NK-001 Human Clinical Trials in Europe

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 3, 2011) - Neurokine Pharmaceuticals Inc. (OTCBB:NEUKF) (the "Company") is pleased to announce that it has signed a contract with Clinical Investigations Group (CIG) of U.K. to conduct Phase II human clinical trials to study the effects of NK-001 in protecting patients against cognitive impairment (Alzheimer's-type) side effects of coronary artery bypass graft (CABG) surgery. CIG will conduct these trials in 50 patients at 3 clinical investigation centers in Europe. These sites have been previously approved by CGI to have outstanding expertise in cardio-surgery and psychiatry. The Company will immediately begin to collaborate with CGI to complete all necessary documentation for submission of approval of its protocol for human clinical trials in Europe.

"I am very pleased to report the signing of the contract with Clinical Investigations Group. In the next 6 to 8 weeks we will work diligently with CGI to complete all our documentation to submit our Phase II protocol to the European authorities for their approval. We look forward to receiving expedited approval from Europe to conduct these trials," said Ahmad Doroudian, President and CEO of Neurokine.

About Neurokine

Neurokine Pharmaceuticals Inc. focuses on development of new use for existing marketed products for diseases mediated by acute and chronic inflammatory reactions. The Company is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate or enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Neurokine or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of Neurokine's products, the competitive environment within the industry, the ability of Neurokine to continue to expand its operations, the level of costs incurred in connection with Neurokine's expansion efforts, economic conditions in the industry and the financial strength of Neurokine's customers and suppliers. Neurokine does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information

  • Neurokine Pharmaceuticals Inc.
    Ahmad Doroudian, Ph.D.
    President and CEO
    (604) 805-7783
    www.neurokine.com